These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 36189211)

  • 1. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
    Front Immunol; 2022; 13():908173. PubMed ID: 35880172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
    Zhang C; Wei F; Ma W; Zhang J
    Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
    Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
    BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions.
    Hong B; Zheng J; Chen R; Zheng C; Du B; Ni R; Yang J
    Drug Saf; 2023 Dec; 46(12):1313-1322. PubMed ID: 37934397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
    Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
    Front Oncol; 2021; 11():662731. PubMed ID: 34221977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine 
in Attenuating the Related Mortality in Mice].
    Chen Z; Wang M; Gao S; Guo H; Wang G; Zhou G
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):394-403. PubMed ID: 34157799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
    Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis.
    Dottorini L; Ghidini A; Deda R; Sarno I; Cavallone M; Luciani A; Petrelli F
    J Geriatr Oncol; 2024 May; 15(4):101741. PubMed ID: 38462434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
    El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
    Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
    Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
    J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
    Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
    Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
    EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.